Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Myeloid

Explore clinical trials studying Leukemia, Myeloid. Study availability and eligibility vary by location and protocol.

3,110 public trials 619 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Myeloid trial results

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

NCT01077544

Conditions
Acute Lymphoblastic Leukemia, Bone Marrow Diseases, Chronic Disease, +18 more
Locations
  • Novartis Investigative Site Bordeaux, Aquitaine, France
  • Novartis Investigative Site Lille, France
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Poitiers, France
View Trial Details
Completed

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

NCT01242774

Conditions
Acute Myeloid Leukemia (AML), Chromosome Aberrations, Hematologic Diseases, +8 more
Locations
  • Stanford University Medical Center Stanford U Stanford, California, United States
  • Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr Boston, Massachusetts, United States
  • Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital Columbus, Ohio, United States
  • Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2) Charleston, South Carolina, United States
View Trial Details
Completed

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

NCT01055483

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Dresden, Germany
  • Novartis Investigative Site Frankfurt, Germany
View Trial Details
Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

NCT01613976

Conditions
Acute Myeloid Leukemia (AML), Bone Marrow Diseases, Chronic Disease, +15 more
Locations
  • Novartis Investigative Site Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site Kobe, Hyōgo, Japan
  • Novartis Investigative Site Sendai, Miyagi, Japan
View Trial Details
Completed

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00093600

Conditions
Acute Myeloid Leukemia (AML), Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +7 more
Locations
  • Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
  • MD Anderson Cancer Center/University of Texas Houston, Texas, United States
View Trial Details
Completed

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT02078609

Conditions
AML and High Risk MDS, Bone Marrow Diseases, Hematologic Diseases, +7 more
Locations
  • Novartis Investigative Site Ann Arbor, Michigan, United States
  • Novartis Investigative Site Prahran, Victoria, Australia
  • Novartis Investigative Site Marseille, France
  • Novartis Investigative Site Ulm, Germany
View Trial Details
Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

NCT01456676

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations
  • Novartis Investigative Site Toronto, Ontario, Canada
  • Novartis Investigative Site Marseille, France
  • Novartis Investigative Site Frankfurt, Germany
  • Novartis Investigative Site Ulm, Germany
View Trial Details

Related conditions